Suppr超能文献

根据 NSCLC 淋巴结清扫范围对国际肺癌研究协会残余肿瘤分类进行重新分类:一刀切并不适合所有情况。

Reclassifying the International Association for the Study of Lung Cancer Residual Tumor Classification According to the Extent of Nodal Dissection for NSCLC: One Size Does Not Fit All.

机构信息

Department of Thoracic and Cardiovascular Surgery, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea.

Department of Epidemiology and Medicine, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.

出版信息

J Thorac Oncol. 2022 Jul;17(7):890-899. doi: 10.1016/j.jtho.2022.03.015. Epub 2022 Apr 21.

Abstract

INTRODUCTION

The extent of nodal assessment may require risk-based adjustments in NSCLC. We reclassified the International Association for the Study of Lung Cancer Residual tumor classification according to the extent of nodal dissection and evaluated its long-term prognosis by tumor stage and histologic subtype.

METHODS

We reclassified 5117 patients who underwent resection for clinical stages I to III NSCLC and had complete or uncertain resection by International Association for the Study of Lung Cancer classification into the following 3 groups according to compliance with three components (N1, N2, and subcarinal node) of systematic nodal dissection criteria: fully compliant group (FCG), partially compliant group (PCG), and noncompliant group (NCG). Recurrence-free survival (RFS) and overall survival (OS) were compared.

RESULTS

Of the 5117 patients, 2806 (55%), 1959 (38%), and 359 (7%) were FCG, PCG, and NCG, respectively. PCG and NCG were more likely to be of lower clinical stage and adenocarcinoma with lepidic component than FCG. The 5-year RFS and OS were significantly better in NCG than in FCG or PCG (RFS, 86% versus 70% or 74%, p < 0.001; OS, 90% versus 80% or 83%, p < 0.001). In particular, NCG had better RFS and OS than FCG or PCG in clinical stage I and in lepidic-type adenocarcinoma.

CONCLUSIONS

In early stage NSCLC with low-risk histologic subtype, a less rigorous nodal assessment was not associated with a worse prognosis. Although surgeons should continue to aim for complete resection and thorough nodal assessment, a uniform approach to the extent and invasiveness of nodal assessment may need to be reconsidered.

摘要

简介

淋巴结评估的范围可能需要根据非小细胞肺癌(NSCLC)的风险进行调整。我们根据淋巴结清扫的范围重新分类国际肺癌研究协会残余肿瘤分类,并根据肿瘤分期和组织学亚型评估其长期预后。

方法

我们根据系统淋巴结清扫标准的三个组成部分(N1、N2 和隆突下淋巴结)的遵守情况,将 5117 例接受临床 I 期至 III 期 NSCLC 切除术且国际肺癌研究协会分类为完全或不确定切除的患者重新分类为以下三组:完全遵守组(FCG)、部分遵守组(PCG)和不遵守组(NCG)。比较无复发生存率(RFS)和总生存率(OS)。

结果

在 5117 例患者中,2806 例(55%)、1959 例(38%)和 359 例(7%)分别为 FCG、PCG 和 NCG。PCG 和 NCG 更有可能处于较低的临床分期和具有贴壁型成分的腺癌。NCG 的 5 年 RFS 和 OS 明显优于 FCG 或 PCG(RFS,86%比 70%或 74%,p<0.001;OS,90%比 80%或 83%,p<0.001)。特别是,在临床 I 期和贴壁型腺癌中,NCG 的 RFS 和 OS 优于 FCG 或 PCG。

结论

在低风险组织学亚型的早期 NSCLC 中,不严格的淋巴结评估与预后不良无关。尽管外科医生应继续努力实现完全切除和彻底的淋巴结评估,但可能需要重新考虑淋巴结评估的范围和侵袭性的统一方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验